OS Therapies Inc
OS Therapies Incorporated (trading on the American exchange) is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments for osteosarcoma and other solid tumors. The company's website is www.ostherapies.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OS Therapies Inc does
In the company’s own words
OS Therapies Incorporated (trading on the American exchange) is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments for osteosarcoma and other solid tumors. The company's website is www.ostherapies.com.
The company's lead product candidate is OST-HER2, a genetically engineered strain of Listeria monocytogenes that expresses HER2 protein epitopes to produce a cellular immune response against cancer cells. OST-HER2 has received orphan drug designation and rare pediatric disease designation from the FDA. In a Phase IIb clinical trial enrolling 41 patients with recurrent osteosarcoma following surgical resection, the candidate met its primary endpoint of 12-month event-free survival, with 33 percent of treated patients remaining recurrence-free at 12 months compared to 20 percent in historical controls. Final two-year overall survival data showed 75 percent of evaluable patients alive two years after their most recent pulmonary resection compared to 40 percent in historical controls. The company announced positive immune biomarker data indicating that activation of interferon gamma pathway markers correlated with overall survival outcomes.
OS Therapies' secondary product candidate is OST-tADC, a next-generation tunable antibody-drug conjugate platform featuring pH-sensitive silicone linkers designed to deliver cytotoxic payloads directly to solid tumors. The lead OST-tADC program targets folate receptor alpha in ovarian and endometrial cancers and is currently in preclinical development.
In April 2025, the company completed acquisition of Listeria-based immune-oncology programs and related intellectual property assets from Ayala Pharmaceuticals, including investigational new drug applications for ADXS-503 in non-small cell lung cancer and ADXS-504 in prostate cancer. The company collaborates with contract research organizations and maintains scientific advisory boards comprising oncology experts, patient advocates and ADC specialists. OS Therapies does not operate manufacturing facilities and relies on third-party contract manufacturers for production of its investigational product candidates.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1795091
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OS Therapies Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OS Therapies Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OS Therapies Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OS Therapies Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OS Therapies Inc's last four quarterly filings that the numbers alone won't show?”